Sodium Salt Adjunct for Rapid Hyperglycemia Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 1 diabetics face challenges in managing hyperglycemia, leading to prolonged periods of high blood sugar levels, which can result in diabetic ketoacidosis, increased hospitalizations, and long-term complications such as cardiovascular issues and kidney damage, with current treatments being inefficient in rapidly reducing hyperglycemic episodes.
Innovation Solution
Administering a therapeutically effective dose of a sodium salt, in combination with insulin, to rapidly lower blood glucose levels to sub-hyperglycemic ranges within 60-90 minutes, using sodium salts like sodium acetate, sodium citrate, and sodium chloride, either orally or in combination with beverages, to address hyperglycemia in Type 1 and Type 2 diabetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional insulin treatment is used to manage hyperglycemia, then blood sugar levels can be reduced, but the correction process takes several hours and requires frequent monitoring and adjustments
Solution Approach 1:
The patent changes the chemical parameter of the treatment by introducing sodium salts (sodium acetate, sodium citrate, sodium bicarbonate) as an adjunct to conventional insulin therapy. These salts alter the metabolic parameters by providing alternative substrates for gluconeogenesis and affecting insulin sensitivity, thereby accelerating the correction of hyperglycemia beyond what insulin alone can achieve.
Solution Approach 2:
The sodium salts act as intermediary substances that facilitate faster blood sugar correction. They mediate between the hyperglycemic state and the desired normal glucose level by providing rapid-acting mechanisms (osmotic diuresis, metabolic alkalosis, gluconeogenesis stimulation) that work in conjunction with insulin to achieve quicker glucose reduction.
2Device complexity
If prolonged hyperglycemia is allowed to occur, then treatment complexity is reduced, but long-term complications such as cardiovascular disease, kidney damage, and nerve damage increase
Solution Approach 1:
The patent applies preliminary action by having patients take sodium salts at the first sign of hyperglycemia (when blood glucose exceeds a predetermined threshold). This early intervention prevents the progression to prolonged hyperglycemia and potential ketoacidosis, addressing the problem before it escalates to require more complex medical intervention.
Solution Approach 2:
The patent uses partial action by implementing a threshold-based treatment approach. Patients only take the sodium salt composition when blood glucose exceeds a specific threshold, rather than continuous treatment. This partial application reduces treatment complexity while still effectively preventing long-term complications by intervening only when necessary.
3Manufacturing precision
If sodium salts are administered to rapidly lower blood glucose, then hyperglycemic episodes are shortened, but sodium intake must be carefully controlled to avoid adverse effects
Solution Approach 1:
The patent changes the dosage parameter by specifying precise amounts of sodium salts (e.g., 1-4 grams of sodium acetate, 1-4 grams of sodium citrate, 1-2 grams of sodium bicarbonate) to be taken only when blood glucose exceeds a threshold. This precise parameter control achieves rapid glucose correction while limiting total sodium exposure to safe levels.
Solution Approach 2:
The patent implements a feedback mechanism where patients monitor their blood glucose levels and only administer sodium salts when a predetermined threshold is exceeded. This feedback-based approach ensures that sodium intake is precisely controlled and only occurs when clinically necessary, preventing both under-treatment and excessive sodium consumption.
Data Source
AI summary
The disclosure describes methods and compositions for reducing the duration of hyperglycemia and treating diabetes and complications thereof. A human subject with hyperglycemia is administered insulin, a water-based beverage, and a sodium salt formulation sufficient to accelerate said subject's return to a non-hyperglycemic state. This process can be repeated multiple times within a given time period.